Professional opinions / statements
GynTect® may supplement cervical cancer screening based on human papillomavirus tests. The data indicate that the test may detect among women tested HPV-positive those who require clarification of their cervical disease status.
oncgnostics has identified and clinically validated its patented biomarkers which may be used in various fields in cancer diagnostics. This allows strategic partners from the pharma and diagnostics field the access to innovative and reliable tests in a growth market.
With GynTect® patients quickly and reliably receive certainty in the clarification of unclear Pap- and HPV results. Thus the test may help to avoid unnecessary invasive diagnostics and treatment and reduce costs in health economy.